

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Even Date Herewith
First Named Inventor	Johan FROSEGARD
Group Art Unit	
Examiner Name	
Attorney Docket Number	FROSTEGARD=1D

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,731,208	.3-24-1998	HEINECKE	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	Not Yet Assigned
		Filing Date	Even Date Herewith
		First Named Inventor	Johan FROSTEGARD
		Group Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	FROSTEGARD=1D

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AB	BALDO et al, "A specific, sensitive, and high capacity immunoassay for PAF". 1991). 26(12):1136-1139.	
	AC	BARQUINERO, Jordi, et al "Antibodies Against Platelet-Activating Factor In Patients With Antiphospholipid Antibodies". Lupus, Vol. 3 (1994), pp. 55-58.	
	AD	FROSTEGARD et al, "Association of Serum Antibodies to Heat-Shock Protein 65 With Borderline Hypertension", HYPERTENSION, 29(1), pp. 40-44, 1997.	
	AE	FROSTEGARD et al, "Platelet-Activating Factor and Oxidized LDL Induce Immune Activation by a Common Mechanism", ARTERIOSCLEROSIS, 17(5), pp 963-968, 1997.	
	AF	HARRIS et al, "Evaluation of the Anti-Cardiolipin Antibody Test: Report of an International Workshop held 4 April 1986:", Clin. Exp Immunol, 1987 Apr; 68(1):215-222.	
	AG	HIRASHIMA Y et al, "Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers". & ACTA Neurochir. (1995) 137(1-2):15-18. (Dialog Information Services, File 154, MEDLINE, Dialog accession no. 08672149, Medline accession no. 96350619)	
	AH	KARASAWA et al, "Radioimmunoassay for platelet activating factor". Lipids. (1991). 26(12):1126-1129.	
	AI	LEMNE et al, "Carotid Intima-Media Thickness and Plaque Borderline Hypertension" STROKE, 26(1); pp. 34-39; 1995	
	AJ	OSTERMANN et al, "The degradation of platelet activating factor in serum and its discriminative value in atherosclerotic patients." Thrombosis Research. (1998). 52:529-540.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.